Welcome to the ValueWiki METHYLGENE INC. J (MYG:CA) article! Register for free or click the "edit" link to contribute!

METHYLGENE INC. J (MYG:CA)

From ValueWiki

Jump to: navigation, search

Launch Chat Window

TSX \ Life Sciences \ Biotechnology & Pharmaceuticals

METHYLGENE INC. is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics with an initial focus on cancer and infectious disease.Summary from Toronto Stock Exchange

1 Company Analysis
2 News Feed
3 Risks
4 Research Links
5 Notes

Today

Max

[edit]

Company Analysis

You can add your own information here - just click the blue edit tab. Or view examples at the Start a new article page.

The edit window has shortcut and help links if you need them.^[1] Be bold!

[edit]

News Feed

11/26/08 2:11 pm	MethylGene to Present at Investor Conferences (Marketwire)
11/18/08 9:11 am	Northern Trust Launches New ETF Tracking FTSE CNBC Global 300 Index (PR Newswire)
11/10/08 7:11 am	MethylGene Reports Third Quarter 2008 Financial Results (Marketwire)
10/27/08 9:10 am	MethylGene Presents Preclinical Data for MGD290, a Hos2 Fungal Inhibitor, at Joint ICAAC/IDSA Annual Meeting (Marketwire)
10/27/08 8:10 am	MethylGene Reacquires Rights to MGCD0103 From Celgene and Implements Strategic Plan to Focus on Development of Proprietary Clinical Pipeline (Marketwire)
10/23/08 6:10 am	MethylGene to Present at the 7th Annual BIO Investor Forum (Marketwire)
10/22/08 6:10 am	MethylGene Presents Preclinical Biomarker Data For MGCD265 at the 20th EORTC-NCI-AACR Symposium (Marketwire)
10/15/08 6:10 am	MethylGene Initiates Phase I Clinical Study With MGCD290 for Fungal Infections (Marketwire)
10/02/08 6:10 am	Methylgene Receives Clinical Trial Approval from Health Canada for its Proprietary Product Candidate MGCD290 for Fungal Infections (Marketwire)
09/19/08 6:09 am	MethylGene Exercises Right to Convert MGCD0103 Collaboration with Celgene to Pre-Determined Royalty and Milestone Arrangement (Marketwire)